Recreational nitrous oxide use in France in 2022: Results from a nationwide representative sample of adults
Drug and Alcohol Review · 2025
DOI: 10.1111/dar.14039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Review, 2025. Verfasst von Tangui Barré und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, Fran…. Hauptthemen laut MEDLINE: Nitrous Oxide, Recreational Drug Use, Health Knowledge, Attitudes, Practice. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Santé Publique France.
Abstract (Originalsprache)
Introduction
The increasing heavy and sustained use of nitrous oxide (N 2 O) for recreational purposes in several countries is a growing public health issue, as it can cause neuropathy and other harms. Documenting recreational N 2 O use prevalence and characteristics of people who use the drug in the general population is essential.
Methods
Between 2 March and 9 July 2022, we conducted a nationwide survey of a random sample of adults in France to estimate the prevalence of N 2 O awareness and reported use. Logistic regression analyses were performed to identify factors associated with reported lifetime recreational N 2 O use.
Results
Of the study's 3229 participants, we estimated that 75.2% (95% confidence interval [CI] 73.2–77.2) of the French adult population had heard of N 2 O, that 4.3% (95% CI: 3.6–5.2) had used it, and that 0.8% (95% CI 0.5–1.3) used it in the past year. Reported lifetime use prevalence was highest in persons aged 18–29 years, at 13.9% (95% CI 10.9–17.5). Reported lifetime use was associated with younger age, being male, a tertiary education diploma (vs. no upper secondary school certificate) and tobacco use. Discussion and Conclusions We estimated that in 2022 three‐quarters of adults in France were aware of recreational N 2 O use, and that 4.3% used it in their lifetime; prevalence was highest in 18–29‐year‐olds. To implement successful interventions to reduce N 2 O‐related risks, its use in specific contexts needs to be explored. Moreover, representative studies focusing exclusively on adolescents and young adults are needed to acquire an in‐depth understanding of N 2 O‐related practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix-Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
- Santé Publique France, Saint-Maurice, France.
- Centre de Recherche en Épidémiologie et Santé des Populations, Inserm U1018, Université Paris-Saclay, Université Paris-Sud, Université Versailles Saint-Quentin, Villejuif, France.
ORCID-Profile: Tangui Barré
Förderung
- Santé Publique France
Zitieren
APA
Barré, T., Lahaie, E., Di Beo, V., Carrieri, P., Andler, R., Nguyen-Thanh, V., & Beck, F. (2025). Recreational nitrous oxide use in France in 2022: Results from a nationwide representative sample of adults. Drug and Alcohol Review. https://doi.org/10.1111/dar.14039
Vancouver
Barré T, Lahaie E, Di Beo V, Carrieri P, Andler R, Nguyen-Thanh V, et al. Recreational nitrous oxide use in France in 2022: Results from a nationwide representative sample of adults. Drug and Alcohol Review. 2025. doi:10.1111/dar.14039
BibTeX
@article{Barr2025,
author = {Barré, Tangui and Lahaie, Emmanuel and Di Beo, Vincent and Carrieri, Patrizia and Andler, Raphaël and Nguyen-Thanh, Viêt and Beck, François},
title = {Recreational nitrous oxide use in France in 2022: Results from a nationwide representative sample of adults},
journal = {Drug and Alcohol Review},
year = {2025},
doi = {10.1111/dar.14039}
}
EUVIMED